Inhibitor Therapeutics, INC 10-Q quarterly reports

Inhibitor Therapeutics reports Q1 2026 net loss of $0.69 million and faces going concern uncertainty following a failed $3 million capital raise.

Inhibitor Therapeutics, Inc. reported an increased nine-month net loss and a significant decline in cash reserves, signaling potential future capital needs despite progress in drug development.

Inhibitor Therapeutics reported a wider net loss and decreased cash in Q2 2025 as it advances its itraconazole drug development for cancer.

Inhibitor Therapeutics reports a net loss for Q1 2025 while progressing with its plan to develop itraconazole-based therapies.

Inhibitor Therapeutics reports its financial results for the third quarter of 2024, highlighting ongoing efforts in drug development and regulatory engagement with the FDA.

Inhibitor Therapeutics reported its financial results for the second quarter of 2024, highlighting ongoing research and development efforts and preparations for a key meeting with the FDA regarding its itraconazole-based cancer therapies.

Inhibitor Therapeutics reported its first quarter 2024 financial results, highlighting ongoing efforts to develop itraconazole-based therapies for various cancers.